Article Sidebar

pdf
Date Published: 30/08/2023
Abstract Views: 102
Views pdf: 94
DOI: https://doi.org/10.51298/vmj.v529i1B.6403
Issue
Vol. 529 No. 1B (2023)
Section
Các bài báo
How to Cite
Nguyễn, H. Đăng, Nguyễn, M. P., & Nguyễn, O. O. (2023). PLASMA OSTEOPROTGERIN CONCENTRATION IN VIETNAMESE MILITARY PILOTS. Vietnam Medical Journal, 529(1B). https://doi.org/10.51298/vmj.v529i1B.6403

PLASMA OSTEOPROTGERIN CONCENTRATION IN VIETNAMESE MILITARY PILOTS

Hải Đăng Nguyễn1,, Minh Phương Nguyễn2, Oanh Oanh Nguyễn3
1 PK-KQ Institute of Medicine
2 Vietnam Military Medical Academy
3 103 Military Hospital

Main Article Content

Abstract

Military pilots (MP) are special subjects, pathology or cardiovascular physiological disorders are the leading cause of MP's inability to fly. Osteoprotegerin is associated with risk factors and cardiovascular disease, but has not been studied in Vietnamese MP. The cross – sectional sudy conducted on 246 male military pilots and a control group with 118 male soldiers, with objectives were evaluating of plasma OPG concentration and relationship with some cardiovascular risks in Vietnamese MP. Survey of cardiovascular risks through clinical and subclinical examination. The plasma OPG concentration was quantified by ELISA method. The results were: The median of plasma OPG in MP was 1485.31 pg/ml, statistically significantly higher than the control group (p<0,001). Plasma OPG concentration increased with age, hypertension and higher in MP with metabolic syndrom, with statistically significant (p<0.01, p<0.001). There was no significant difference in OPG levels in the MP group with dyslipidemia, overweight and obesity (p>0.05).

Article Details

Keywords

military pilot, osteorotegerin, cardiovascular risk

References

Bernardi, S., et al. (2016), "Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease", Biomed Res Int. 2016, p. 1752854.
2. DeJohn, C. A., et al. (2018), "Cardiac Inflight Incapacitations of U.S. Airline Pilots: 1995-2015", Aerosp Med Hum Perform. 89(9), pp. 837-841.
3. Gannage-Yared, M. H., et al. (2006), "Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population", Clin Endocrinol (Oxf). 64(6), pp. 652-8.
4. Perez de Ciriza, C., et al. (2014), "Circulating osteoprotegerin is increased in the metabolic syndrome and associates with subclinical atherosclerosis and coronary arterial calcification", Clin Biochem. 47(18), pp. 272-8.
5. Bộ Quốc Phòng (2014), Điều lệ Giám định Y khoa Không quân.
6. Praskurnichiy, E. A., et al. (2017), "Aeromedical Aspects of Factor Risk Management for Flight Safety", Human Physiology. 43(7), pp. 840-845.
7. Van Campenhout, A. and Golledge, J. (2009), "Osteoprotegerin, vascular calcification and atherosclerosis", Atherosclerosis. 204(2), pp. 321-9.
8. Shimizu, H., et al. (2008), "Angiotensin II accelerates osteoporosis by activating osteoclasts", Faseb j. 22(7), pp. 2465-75.